Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The Baltimore Buprenorphine Initiative: understanding the role of buprenorphine in addressing heroin addiction in an urban-based community.

Murphy LS, Oros MT, Dorsey SG.

J Addict Nurs. 2014 Jan-Mar;25(1):16-25; quiz 26-7. doi: 10.1097/JAN.0000000000000014. Erratum in: J Addict Nurs. 2015 Jan-Mar;26(1):52.

PMID:
24613946
2.

Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients.

Poirier MF, Laqueille X, Jalfre V, Willard D, Bourdel MC, Fermanian J, Olié JP.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):267-72.

PMID:
14751421
3.

Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH.

Am J Public Health. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14.

4.

Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users.

Gandhi DH, Jaffe JH, McNary S, Kavanagh GJ, Hayes M, Currens M.

Addiction. 2003 Apr;98(4):453-62.

PMID:
12653815
5.

Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy.

Pajusco B, Chiamulera C, Quaglio G, Moro L, Casari R, Amen G, Faccini M, Lugoboni F.

Int J Environ Res Public Health. 2012 Mar;9(3):932-42. doi: 10.3390/ijerph9030932. Epub 2012 Mar 16.

6.
7.

Role of buprenorphine in the management of heroin addiction.

Sung S, Conry JM.

Ann Pharmacother. 2006 Mar;40(3):501-5. Epub 2006 Jan 24. Review.

PMID:
16434562
8.

Heroin detoxification with buprenorphine on an inpatient psychiatric unit.

DiPaula BA, Schwartz R, Montoya ID, Barrett D, Tang C.

J Subst Abuse Treat. 2002 Oct;23(3):163-9.

9.

Buprenorphine in the treatment of heroin addiction: déjà vu all over again.

Stimmel B.

J Addict Dis. 2012;31(1):1-2. doi: 10.1080/10550887.2011.643179. No abstract available.

PMID:
22356663
10.

Maintenance drugs to treat opioid dependence.

Farrell M, Wodak A, Gowing L.

BMJ. 2012 May 15;344:e2823. doi: 10.1136/bmj.e2823. No abstract available.

PMID:
22589497
11.

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG.

J Subst Abuse Treat. 2000 Apr;18(3):277-81.

PMID:
10742642
12.

Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study.

Tamaskar R, Parran TV Jr, Heggi A, Brateanu A, Rabb M, Yu J.

J Addict Dis. 2003;22(4):5-12.

PMID:
14723474
13.

A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE, Fitzgerald TT, Vocci FJ.

Drug Alcohol Depend. 2017 Mar 1;172:34-42. doi: 10.1016/j.drugalcdep.2016.11.037. Epub 2017 Jan 11.

PMID:
28107680
14.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.

15.

A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.

Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE.

J Addict Med. 2014 May-Jun;8(3):176-82. doi: 10.1097/ADM.0000000000000035.

PMID:
24695018
16.

Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.

Messinis L, Lyros E, Andrian V, Katsakiori P, Panagis G, Georgiou V, Papathanasopoulos P.

Hum Psychopharmacol. 2009 Oct;24(7):524-31. doi: 10.1002/hup.1050.

PMID:
19650155
17.

A novel community-based buprenorphine program: client description and initial outcomes.

Daniels AM, Salisbury-Afshar E, Hoffberg A, Agus D, Fingerhood MI.

J Addict Med. 2014 Jan-Feb;8(1):40-6. doi: 10.1097/ADM.0000000000000004.

PMID:
24394496
18.

Clinical case conference: unobserved "home" induction onto buprenorphine.

Lee JD, McNeely J, Grossman E, Vocci F, Fiellin DA.

J Addict Med. 2014 Sep-Oct;8(5):309-14. doi: 10.1097/ADM.0000000000000060.

PMID:
25254668
19.

Heroin anticraving medications: a systematic review.

Fareed A, Vayalapalli S, Casarella J, Amar R, Drexler K.

Am J Drug Alcohol Abuse. 2010 Nov;36(6):332-41. doi: 10.3109/00952990.2010.505991. Epub 2010 Oct 19. Review.

PMID:
20955107

Supplemental Content

Support Center